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Abstract
We investigated whether one of the Wnt receptors, frizzled-7 (FZD7), functions in the canonical Wnt signaling path-
way of colorectal cancer (CRC) cells harboring an APC or CTNNB1 mutation and may be a potential therapeutic
target for sporadic CRCs. The expression level of FZD gene family members in colon cancer cells and primary CRC
tissues were determined by real-time PCR. Activation of the Wnt signaling pathway was evaluated by TOPflash
assay. The expression level of Wnt target genes was determined by real-time polymerase chain reaction and/or
Western blot analysis. Cell growth and cell invasion were assessed by MTS and matrigel assays, respectively.
Among 10 FZD gene family members, FZD7 mRNA was predominantly expressed in six colon cancer cell lines
with APC or CTNNB1 mutation. These six cell lines were transfected with FZD7 cDNA together with a TOPflash
reporter plasmid, resulting in a 1.5- to 24.3-fold increase of Tcf transcriptional activity. The mRNA expression levels
of seven known Wnt target genes were also increased by 1.5- to 3.4-fold after transfection of FZD7 cDNA into HCT-
116 cells. The six cell lines were then cotransfected with FZD7-siRNA and a TOPflash reporter plasmid, which re-
duced Tcf transcriptional activity to 20% to 80%. FZD7-siRNA was shown to significantly decrease cell viability and
in vitro invasion activity after transfection into HCT-116 cells. Our present data demonstrated that FZD7 activates the
canonical Wnt pathway in colon cancer cells despite the presence of APC or CTNNB1mutation and that FZD7-siRNA
may be used as a therapeutic reagent for CRCs.
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Introduction
The canonical Wnt signaling pathway that controls cell fate and pro-
liferation is initiated by binding of Wnt ligands to the transmembrane
receptors, frizzleds and low-density lipoprotein receptor–related pro-
teins. The resultant signals prevent β-catenin phosphorylation by a
multiprotein complex composed of adenomatous polyposis coli
(APC), glycogen synthase kinase 3β, casin kinase 1, and axins, and
its subsequent proteosomal degradation. β-Catenin associates with T-
cell factor (TCF)/lymphocyte enhancer transcription factors to acti-
vate target genes that are involved in cell survival, proliferation, or
invasion [1,2]. This signaling pathway is activated in most sporadic
colorectal cancers (CRCs; up to 80%), which is mainly caused by
mutations of APC [3,4]. Mutations of the β-catenin gene, CTNNB1,
most of which preclude its phosphorylation, are also detected but
only in a small proportion of cases (∼10%) [4]. APC mutations mostly
bring about the deletion of the C-terminal half of the protein, leading
to the failure to assemble a functional destruction complex, which
ultimately results in the constitutive stabilization of β-catenin [3,4].
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Until recently, little attention was paid to the role of Wnt ligands or
receptors that function upstream of APC in CRCs.
We have demonstrated that secreted frizzled-related proteins, the
Wnt antagonists that were frequently down-regulated (>90%) by
promoter hypermethylation in CRCs, decreased colony formation
and induced apoptosis when overexpressed in colon cancer HCT-
116 or SW-480 cells with CTNNB1 or APC mutations, respectively,
suggesting that Wnt ligands could affect the proliferation and survival
of the CRC cells with these mutations [5]. Another Wnt antagonist,
Wnt inhibitory factor 1 (WIF-1), was thereafter revealed to be epi-
genetically inactivated in CRCs, and its overexpression in SW-480
cells induced apoptosis [6]. In that report, cell death was also induced
by the suppression of Wnt-1 with small interfering RNA (siRNA) or
a monoclonal antibody in cell lines (SW-480 and HCT-116) or in
primary cultured colon cancer cells. These findings suggest that Wnt
ligands and receptors may be promising therapeutic targets for spo-
radic CRCs.
Frizzled-7 (FZD7 ) is 1 of 10 members of the frizzled gene family.
Its expression is limited in normal tissues. The mRNA has been de-
tected in fetal kidney and lung and in adult skeletal muscle, heart,
brain, and placenta [7]. In contrast, FZD7 mRNA has been found
in a wide variety of cancer cells including melanoma, lung cancer [7],
esophageal cancer [8], gastric cancer [9], colon cancer [7,10,11], he-
patocellular carcinoma [12], and lymphoblastic leukemia [13]. A re-
cent study using in situ hybridization showed that FZD7 mRNA
expression was confined to the epithelium of the crypt bottom of
the colon [14], suggesting that it is expressed by immature colono-
cytes. Activation of the canonical Wnt pathway with FZD7 in cancer
cells was suggested by previous studies using esophageal cancer
KYSE150 cells [8], several kinds of hepatocellular carcinoma cells
[12], and colon cancer LIM1863 cells [11]. However, to the best
of our knowledge, there is no information about FZD7 in colon can-
cer cells harboring the APC or CTNNB1 mutation. In this study, we
investigated whether FZD7 functions as a receptor for the canonical
Wnt signaling pathway in the colon cancer cells and may be a poten-
tial therapeutic target for sporadic CRCs.
Materials and Methods
Cell Cultures
Human colon cancer cell lines SW-480, HCT-116, DLD-1, LoVo,
and HT-29 were purchased from American Type Culture Collection
(ATCC, Manassas, VA). Human colon cancer Caco-2 and human em-
bryonic kidney 293T cells were purchased from RIKEN BRC (Tsukuba,
Japan). 293T cells were cultured in DMEM (Nissui Pharmaceuti-
cal, Tokyo, Japan) supplemented with 10% heat-inactivated fetal bo-
vine serum (FBS; ATCC), 100 IU/ml penicillin, and 100 μg/ml
streptomycin (Sigma, St. Louis, MO). SW-480 cells were cultured
in Leibovitz’s L-15 medium (Gibco/Invitrogen, Carlsbad, CA) sup-
plemented with 10% heat-inactivated FBS, 100 IU/ml penicillin,
and 100 μg/ml streptomycin. HCT-116 and HT-29 cells were cul-
tured in McCoy’s 5A medium (Gibco) supplemented with 10% heat-
inactivated FBS, 100 IU/ml penicillin, and 100 μg/ml streptomycin.
DLD-1 cells were cultured in RPMI 1640 medium (Gibco) sup-
plemented with 10% heat-inactivated FBS, 100 IU/ml penicillin,
and 100 μg/ml streptomycin. Caco-2 cells were cultured in mini-
mum essential medium (Eagle; Sigma) supplemented with 20%
heat-inactivated FBS, 100 IU/ml penicillin, and 100 μg/ml strepto-
mycin. LoVo cells were cultured in Ham’s F-12K medium (SIGMA)
supplemented with 10% heat-inactivated FBS, 100 IU/ml penicillin,
and 100 μg/ml streptomycin.
Primary CRC Tissues
Primary CRC tissues (n = 13) were obtained from the patients
who underwent surgical operation in our institution. Mean age
was 68.2 years (range, 48–83 years), and male/female ratio was
3:10. According to pTNM classification, three patients were in stage
II, four in stage III, and six in stage IV. Written informed consent
was obtained from those patients, and the experimental protocol
was approved by the institutional ethics committee of the Yamaguchi
University Graduate School of Medicine.
Plasmid Construction
Human frizzled-1 (FZD1), frizzled-6 (FZD6 ), and frizzled-7
(FZD7 ) were amplified from human testis total RNA (Clontech,
Palo Alto, CA) by transcription–polymerase chain reaction (RT-
PCR). The following primers were used: FZD1 forward primer,
5′-gccgagaaagtatggctgcgg-3′; FZD1 reverse primer, 5′-agcctgcgaaa-
gagagttgtc-3′; FZD6 forward primer, 5′-gaattctaattgacccaggactca-
ttttcag-3′; FZD6 reverse primer, 5′-ctcgagccagtgtaacacaaatttgcttctg-3′;
FZD7 forward primer, 5′-gcctcgtcgcactcctcag-3′; FZD7 reverse primer,
5′-ggggctcataccgcagtctc-3′. Polymerase chain reaction products were
cloned into pTargeT-Mammalian Expression Vector System (Promega,
Madison, WI). pcDNA3.1-FZD1 and pcDNA3.1-FZD7 were ob-
tained by subcloning a NheI– EcoRI fragment from pTargeT-FZD1
and pTargeT-FZ7 into the NheI– EcoRI site of pcDNA3.1 (Invitro-
gen). pcDNA3.1-FZD6 were obtained by subcloning a EcoRI– XhoI
fragment from pTargeT-FZD6 into the EcoRI– XhoI site of
pcDNA3.1. EcoRI– EcoRI fragments of pTargeT-FZD7 were sub-
cloned into the EcoRI site of pEF4-V5 (Invitrogen). The following pri-
mers were used: FZD7 forward primer, 5′-gccatgggccaggtagac-3′;
FZD7 reverse primer, 5′-ttcgaataccgcagtctcccccttgc-3′. The PCR pro-
ducts were cloned into pGEM-T Easy Vector (Promega). pEF-FZD7-V5
was obtained by subcloning a BlpI– BstBI fragment from pGEM-T-
FZD7 into the BlpI– BstBI site of pEF4-FZD7.
Transfection
Cells growing in culture dishes were transfected at 50% to 70%
confluence by FuGENE HD (Roche Diagnostics, Basel, Switzerland)
according to the manufacturer’s instructions.
Quantitative PCR
Total RNA was isolated from colon cancer cell lines using the
RNeasy Mini Kit (Qiagen, Hilden, Germany). The total RNA from
primary CRC tissues was isolated using TRIzol (Invitrogen). The
extracted total RNA was reverse-transcribed into single-stranded
cDNA using High Capacity cDNA Archive Kit (Applied Bio-
systems, Warrington, UK). Real-time PCR was performed using
first-strand cDNA with TaqMan Universal PCR Master Mix (Ap-
plied Biosystems). The assay numbers for the endogenous control
(GAPDH) and target genes were as follows: 4326317 (GAPDH);
Hs00268943_s1 ( frizzled-1); Hs00361432_s1 ( frizzled-2);
Hs00184043_m1 ( frizzled-3); Hs00201853_m1 ( frizzled-4);
Hs00361869_g1 ( frizzled-5); Hs00171574_m1 ( frizzled-6);
Hs00275833_s1 ( frizzled-7 ); Hs00259040_s1 ( frizzled-8);
Hs00268954_s1 ( frizzled-9); and Hs00273077_s1 ( frizzled-10).
Quantitative PCR was performed on an ABI Prism 7900HT Se-
quence Detection System (Applied Biosystems). Quantitative PCR
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parameters for cycling were as follows: 50°C for a 2-minute hold, 95°
C for 10 minutes of 40 cycles of PCR at 95°C for 15 seconds, and
60°C for 1 minute. All reactions were done in a 20-μl reaction vol-
ume in triplicate. The mRNA expression level was determined using
the 2 −Δ CT method.
For target gene assays and interferon assay, total RNA was isolated
from colon cancer cell lines using the RNeasy Mini Kit (Qiagen)
48 hours after transfection. The extracted total RNA was reverse-
transcribed into single-stranded cDNA using High Capacity cDNA
Archive Kit (Applied Biosystems). Real-time PCR was performed us-
ing first-strand cDNA with Power SYBR Green PCR Master Mix
(Applied Biosystems). The primers used were as follows:Myc forward
primer, 5′-tcaagaggtgccacgtctcc-3′; Myc reverse primer, 5′-tcttggcag-
caggatagtcctt-3′; Cyclin D1 forward primer, 5′-ccgtccatgcggaagatc-3′;
Cyclin D1 reverse primer, 5′-atggccagcgggaagac-3′; CD44 forward
primer, 5′-caggtttggtggaagatttgg-3′; CD44 reverse primer, 5′-tgtca-
gagtagaagttgttggatgg-3′; VEGF forward primer, 5′-gccttgccttgctgc-
tctac-3′; VEGF reverse primer, 5′-atgattctgccctcctccttc-3′; Survivin
forward primer, 5′-cggttgcgctttcctttc-3′; Survivin reverse primer, 5′-
tgttcttggctctttctctgtcc-3′; Id-2 forward primer, 5′-gacccgatgagcctgctata-
ca-3′; Id-2 reverse primer, 5′-ggtgctgcaggatttccatct-3′; Jun forward
primer, 5′-ggaaacgaccttctatgacgatg-3′; Jun reverse primer, 5′-agggtca-
tgctctgtttcagg-3′; OAS1 forward primer, 5′-gtcttcctcagtcctctcaccac-3′;
OAS1 reverse primer, 5′-gagcctggacctcaaacttcac-3′; GAPDH forward
primer, 5′-ccatgttcgtcatgggtgtg-3′; GAPDH reverse primer, 5′-ggtgc-
taagcagttggtggtg-3′. Quantitative PCR was performed on an ABI Prism
7900HT Sequence Detection System (Applied Biosystems). Quantita-
tive PCR parameters for cycling were as follows: 95°C for 10 minutes of
40 cycles of PCR at 95°C for 15 seconds, and 60°C for 1 minute. All re-
actions were done in a 20-μl reaction volume in triplicate. The mRNA
expression level was determined using the 2 −Δ CT method.
Luciferase Reporter Assay
For Tcf luciferase assays, cells were transfected with 0.1 μg of
TOPflash (Upstate, Lake Placid, NY), 0.1 μg of pcDNA3.1,
pcDNA3.1-FZD1, pcDNA3.1-FZD6, pcDNA3.1-FZD7, piGENE
or piGENE-FZD7, and 0.005 μg of pRL-TK Vector (Promega) ac-
cording to the manufacturer’s instructions. The total amount of
DNA was adjusted to equal amounts with empty vector. At 48 hours
after transfection, the luciferase levels were measured by using the
Dual-Luciferase Reporter Assay System (Promega). Data are pre-
sented as mean values and SD for three independent experiments
compared with the level of luciferase activity obtained in the presence
of empty vector that is presented as 1.
Western Blot Analysis
After plasmid transfection, cells were washed in ice-cold phosphate-
buffered saline and resuspended in cold buffer containing 10 mM
HEPES, pH 7.9, 10 mM KCl, 1 mM dithiothreitol, 0.1 mM EGTA,
0.1 mM EDTA, and 0.5 mM phenylmethylsulfonyl fluoride. Resus-
pended cells were lysed in 0.5% Nonidet P-40 for 15 minutes fol-
lowed by centrifugation at 1000 g for 5 minutes at 4°C. A total of
10 μg of cytosolic fraction was analyzed by Western blot analysis using
mouse monoclonal antibody or rabbit polyclonal antibody, and anti-
mouse and -rabbit IgG HRP-conjugated secondary antibodies (Dako,
Glostrup, Denmark) were visualized with a LumiGLO Reagent and
Peroxidet (Cell Signaling Technology, Beverly, MA).
Primary antibodies used were mouse anti–β-catenin (BD Bio-
sciences, San Jose, CA), anti-Myc (Novus Biologicals, Littleton, CO),
anti-Jun (BD Biosciences), anti-V5 (Invitrogen), anti–caspase-3 (BD
Biosciences), anti–cytochrome c (BDBiosciences), anti–β-actin (Abcam,
Cambridge, UK) monoclonal antibodies, rabbit anti-FZD7 (Aviva
Systems Biology, San Diego, CA) and anti–survivin polyclonal anti-
body (Abcam).
RNA Interference
Small interfering RNA were constructed in the piGENE hU6 Vec-
tor (Clontech). The 21-nucleotide target sequence for FZD7 was 5′-
tcacctacctggtggacatgc-3′. pcDNA3.1-U6 and pcDNA3.1-U6FZD7-
siRNA were obtained by subcloning a EcoRI– HindIII fragment from
piGENE and piGENE-FZD7 into the EcoRI– HindIII site of
pcDNA3.1.
Interferon Assay
HCT-116 and Caco-2 cells were transfected with piGENE or pi-
GENE-FZD7 or treated with 1 μg/ml poly(I:C) (InvivoGen, San Diego,
CA). At 24 or 48 hours after transfection, total RNA was isolated
from cells and analyzed by real-time PCR for 2′,5′-oligoadenylate
synthetase (OAS1).
Cell Viability Assay
HCT-116 and HT-29 cells were transfected with pcDNA3.1-U6
or pcDNA3.1-U6FZD7. At 24 or 48 hours after transfection, cells
were maintained in medium supplemented with 500 μg/ml G418.
During 6 or 17 days after transfection, cell viability was measured by
the MTS (3-(4,5-dimethylthiazol-2-yl-5-(3-carboxymethoxyphenyl-
2-(4-sulfonphenyl)-2H -tetrazolium, inner salt) assay. The CellTiter
96 AQueous One Solution Cell Proliferation Assay (Promega) was
used for the MTS assay, and instructions from the manufacturer
were followed.
Cell Invasion Assay
Matrigel (1:5; BD Biosciences) was added to the Transwell mem-
brane filter inserts with 8.0-μm pore size (Costar, Cambridge, MA)
and was incubated for 5 hours at 37°C in a 5% CO2 tissue culture in-
cubator. HCT-116 and HT-29 cells were transfected with pcDNA3.1-
U6 or pcDNA3.1-U6FZD7. At 24 or 48 hours after transfection, cells
were harvested and resuspended in serum-free medium supplemented
with 500 μg/ml G418. An aliquot (105 cells) of the prepared cell sus-
pension was added into the upper chamber and cultured into the lower
chamber filled with 600 μl of culture medium containing 5 μg/ml
fibronectin (Sigma), as an adhesive substrate for 48 hours at 37°C
in a 5% CO 2 tissue culture incubator. Invasive cells were stained with
Diff-Quick solution (Fisher Scientific, Pittsburgh, PA). Cells were
counted under a microscope. The average number of cells in five fields
per membrane was counted in triplicate assay.
Results
The mRNA Expression Level of Frizzled Family Members in
Colon Cancer Cell Lines
To reveal the expression of FZD gene family members in colon can-
cer cells harboring the APC or CTNNB1 mutation, the mRNA levels
of 10 FZD genes in SW-480, HCT-116, Caco-2, DLD-1, LoVo, and
HT-29 cells were examined by real-time PCR (Figure 1A). All the cell
lines tested, except for HCT-116, possess the APC mutation [15,16].
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HCT-116 exhibits the CTNNB1 mutation [16]. Among the 10 FZD
genes, FZD6 and FZD7 were predominantly expressed in all cell
lines. The protein levels of FZD7 in six colon cancer cells was indi-
cated by Western blot analysis. 293T cells was transfected with FZD7
as a positive control (Figure 1B).
Effect of FZD7 Overexpression on Tcf-reporter
Transcriptional Activity
Because FZD6 has been shown to be involved in the noncanonical
Wnt pathway [17], we examined whether FZD7 functions as a recep-
tor transducing the canonical Wnt signaling in colon cancer cells. Six
colon cancer cells were transfected with FZD1, FZD6, or FZD7
cDNA together with a TOPflash reporter plasmid. FZD1 was used
as a positive control because FZD1 is known to activate the canonical
pathway [18]. FZD6 was used as a negative control because it is
known to activate the noncanonical Wnt pathway. As shown in Fig-
ure 2A, Tcf transcriptional activity was increased by 1.5- to 24.3-fold
when FZD7 was transfected, suggesting that FZD7 could activate the
canonical pathway in colon cancer cells.
Real-Time PCR and Western Blot Analyses of Expression of
Wnt Target Genes in FZD7-Transfected HCT-116 Cells
To assess whether FZD7 indeed affected the expression of target
genes of the canonical pathway, we transfected FZD1 or FZD7
Figure 1. The mRNA and protein expression level of frizzled family members in colon cancer cell lines. (A) The extracted total RNA was
reverse-transcribed into single-stranded cDNA. Real-time PCR was performed using first-strand cDNA with TaqMan. GAPDH was used
as an endogenous control. Data are presented as mean values and SD for three independent experiments compared with the level of
FZD1 that is presented as 1. (B) Western blot analysis of protein expression of FZD7 in six colon cancer cells. 293T cells was transfected
with FZD7 as a positive control.
700 FZD7 as a Potential Therapeutic Target in CRC Ueno et al. Neoplasia Vol. 10, No. 7, 2008
cDNA into HCT-116 cells and measured the levels of mRNA ex-
pression of seven known target genes including Myc, Cyclin D1,
CD44, VEGF, Survivin, Id-2, and Jun using real-time PCR. The
transcriptional levels of these genes increased 1.5- to 3.4-fold with
FZD7 transfection compared to mock transfection (Figure 2B).
We then performed Western blot analysis of FZD7-transfected
HCT-116 cells for cytosolic β-catenin, Myc, Survivin and Jun pro-
teins. β-Catenin was up-regulated in HCT-116 after FZD7 transfec-
tion (Figure 2C ). The expression levels of Myc, Survivin, and Jun were
also increased, which was consistent with the results of real-time PCR.
FZD7-siRNA Specifically Inhibits the Expression of FZD7
We constructed an expression vector harboring siRNA against
FZD7 (FZD7-siRNA) to investigate the effect of decreased FZD7
expression. Initially, FZD7-V5 and FZD7-siRNA were cotransfected
Figure 2. Effects of FZD7 overexpression on canonical Wnt signaling. (A) Effects of FZD7 overexpression on Tcf-reporter transcriptional
activiry. Colon cancer cell lines were transiently cotransfected with either mock, FZD1, FZD6, or FZD7, TOPflash reporter plasmid, and
pRL-TK plasmid encoding Renilla luciferase as an internal control for transfection efficiency. At 48 hours after transfection, cell lysates
were measured for relative luciferase activities. Data are presented as mean values and SD for three independent experiments com-
pared with the level of luciferase activity obtained in the presence of mock that is presented as 1. (B) Real-time PCR analysis of expres-
sion of Wnt target genes in HCT-116 cells transfected with mock, FZD1, or FZD7. HCT-116 cells were transiently transfected with mock,
FZD1, or FZD7. At 48 hours after transfection, total RNA were reverse-transcribed and amplified with primers specific for each indicated
Wnt target as described in the Materials and Methods section. (C) Western blot analysis of expression of Wnt target genes in HCT-116
cells transfected with mock, FZD1, or FZD7. HCT-116 cells were transiently transfected with mock, FZD1, or FZD7. At 48 hours after
transfection, each cytosolic protein was prepared, and 10 μg of each was subjected to electrophoresis. Expression of β-catenin, Myc,
Survivin, and Jun were assessed. β-Actin served as a loading control.
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into 293T cells, and the whole proteins were subjected to immuno-
blot analysis with an anti-V5 antibody. As shown in Figure 3A,
FZD7-siRNA abolished the expression of FZD7-V5 protein, con-
firming the inhibitory action of the siRNA.
Effects of FZD7-siRNA on Tcf-Reporter Transcriptional
Activity and Expression Level of Wnt Target Genes
The effect of FZD7-siRNA on the canonical Wnt signal–transducing
activity of FZD7 was then observed in six colon cancer cell lines. The
cells were transfected with piGENE or FZD7-siRNA together with a
TOPflash reporter plasmid, and Tcf transcriptional activity was mea-
sured in the same manner as in Figure 2A. We found that Tcf activity
was decreased by 20% to 80% with FZD7-siRNA (Figure 3B).
The effect of FZD7-siRNA on the expression level of target proteins
of the canonical pathway was finally examined in HCT-116 cells trans-
fected with piGENE or FZD7-siRNA. As shown in Figure 3C , the
band intensities of β-catenin, Myc, Survivin, and Jun were decreased
by FZD7-siRNA transfection. These data suggested that FZD7 is in-
volved in the activation of the canonical Wnt pathway in colon cancer
cells despite the presence of the APC or CTNNB1 mutation.
Effects of FZD7-siRNA on Cell Viability and Cell Invasion
We tested whether FZD7-siRNA affects cell viability and migra-
tion to evaluate its potential therapeutic effects on colon cancer cells.
HCT-116 and HT-29 cells were transfected with pcDNA3.1-U6 or
pcDNA3.1-U6FZD7-siRNA, and the number of viable cells selected
Figure 3. Effects of FZD7-siRNA on canonical Wnt signaling. (A) FZD7-siRNA specifically inhibits the expression of FZD7. 293T cells
were transiently transfected with various combinations of pEF4, pEF4-FZD-V5, piGENE, and FZD7-siRNA. A total of 30 μg of cell lysates
was analyzed by Western blot analysis using anti-V5 or anti–β-actin antibodies. (B) Effects of FZD7-siRNA on Tcf-reporter transcriptional
activity. Colon cancer cell lines were transiently cotransfected with either piGENE or FZD7-siRNA, TOPflash reporter vector, and pRL-TK
plasmid encoding Renilla luciferase as an internal control for transfection efficiency. At 48 hours after transfection, cell lysates were
measured for relative luciferase activities. Data are presented as mean values and SD for three independent experiments compared with
the level of luciferase activity obtained in the presence of piGENE that is presented as 1. (C) Western blot analysis of the expression of
Wnt target genes in HCT-116 cells transfected with piGENE or FZD7-siRNA. HCT-116 cells were transiently transfected with piGENE or
FZD7-siRNA. At 48 hours after transfection, 10 μg of cytosolic protein was prepared. Expression of β-catenin, Myc, Survivin, and Jun
were assessed. β-Actin served as a loading control.
702 FZD7 as a Potential Therapeutic Target in CRC Ueno et al. Neoplasia Vol. 10, No. 7, 2008
by G418 was measured by MTS assay 6 or 17 days after transfection
(Figure 4A). As the growth of HT-29 was much slower than HCT-
116, the longer incubation time was required for the evaluation of
HT-29 viability. The viable cell number in HCT-116 and HT-29
was decreased to 20% or 80%, respectively. A significant impairment
of cell viability activity was observed in HCT-116 (P = .0042) and
HT-29 cells (P = .0256) FZD7-siRNA transfer compared to vector con-
trol alone. G418 selection was used for excluding nontransfected cells.
FZD7-siRNA also affected the in vitro invasion activity of HCT-
116 and HT-29 cells. The cell invasion number in HCT-116 and
HT-29 was decreased to 40% or 60%, respectively. A significant im-
pairment of cell invasion activity was observed in HCT-116 (P =
.0002) and HT-29 cells (P = .0006; Figure 4B).
FZD7-siRNA Does Not Induce Interferon Response
Gene, OAS1
To exclude the possibility that FZD7-siRNA triggers an inter-
feron response in colon cancer cells, HCT-116 and Caco-2 cells were
transfected with piGENE or FZD7-siRNA, and the interferon re-
sponse was observed using real-time PCR for OAS1. As shown in
Figure 4C , OAS1 expression was induced by poly(I:C), used as a pos-
itive control, whereas it was not found at all after piGENE or FZD7-
siRNA transfection.
FZD7-siRNA Does Not Induce Apoptosis
The effect of FZD7-siRNA on the expression level of apoptotic
proteins was examined in HCT-116 cells transfected with piGENE
or FZD7-siRNA. As shown in Figure 5A, neither cleavage of cas-
pase-3 nor increase of cytochrome c release was detected by FZD7-
siRNA transfection.
The mRNA Expression Level of FZD7 in Primary CRC
To reveal the expression of FZD7 in primary CRC, the mRNA lev-
els of FZD7 in surgically resected cancer tissues were examined by real-
time PCR (Figure 5B). The FZD7 expression level of primary cancer
tissues was various, but it was equivalent to that of cell lines in about
half of the cases.
Discussion
Our present data demonstrate that FZD7 is the predominantly ex-
pressed member of the frizzled gene family and activates the canon-
ical Wnt signaling pathway in colon cancer cells possessing the APC
or CTNNB1 mutation. Overexpression of FZD7 in these cell lines
caused an increase of Tcf transcriptional activity and expression of
target genes of the canonical Wnt pathway (Figure 2). More impor-
tantly, FZD7-siRNA decreased Tcf activity and Wnt target gene ex-
pression (Figure 3, B and C ), suggesting that FZD7 transmits the
canonical Wnt signals to downstream molecules despite the presence
of APC or CTNNB1 mutation. The findings seem to be compatible
with the “just right” hypothesis for APC mutations in CRCs [3]. Ac-
cumulating evidence suggests that a pertinent combination of the
first hit and second hit provides a superior growth advantage for tu-
mor cells [3]. Resultant truncated APC proteins are almost invariably
retained in CRC cells, and many of them preserve some ability to
bind and, perhaps, degrade β-catenin [3,4]. With regard to the
CTNNB1 mutation, WNT signaling controls the phosphorylation
status through several different crucial serine and threonine sites,
and hence it may be surmised that even if mutation occurs in one
site, other sites will be phosphorylated to adjust the level suitable
for tumor cell survival and proliferation [5]. Indeed, individual CRCs
Figure 4. Functional effects of FZD7-siRNA in HCT-116 and HT-29
cells. (A) Effect of FZD7-siRNA on cell viability. HCT-116 and HT-29
cells were transiently transfected with pcDNA3.1-U6 or pcDNA3.1-
U6FZD7-siRNA. At 24 or 48 hours after transfection, HCT-116 and
HT-29 cells were maintained in medium supplemented with G418.
During 6 or 17 days after transfection, cell viability was tested by
the MTS assay. (B) Effect of FZD7-siRNA on cell invasion. HCT-116
and HT-29 cells were transiently transfected with pcDNA3.1-U6 or
pcDNA3.1-U6FZD7-siRNA. At 24 or 48 hours after transfection, an
aliquot (105 cells) of the prepared cell suspension was added into
the upper chamber and cultured into the lower chamber filled with
the culture medium containing fibronectin for 48 hours. Invasive
cells were stained, and the average number of cells in five fields
per membrane was counted in triplicate assay. (C) Effect of FZD7-
siRNA on interferon response gene, OAS1. HCT-116 and Caco-2
cells were transiently transfected with piGENE or FZD7-siRNA. At
48 hours after transfection, total RNA were reverse-transcribed
and amplified with primers specific for OAS1 as described in the
Materials and Methods section. Poly(I:C) served as a positive con-
trol. OAS1 expression was normalized to GAPDH mRNA. Caco-2
served as a negative control.
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with CTNNB1 mutations contain only one mutant site at a time
[16,19,20].
We then investigated the effect of FZD7-siRNA on the viability of
HCT-116 and HT-29 cells under G418 selection and found that
it exhibited a significant suppressive activity, especially in HCT-
116 cells (Figure 4A). However, this siRNA did not induce apoptosis
of HCT-116 cells as shown in Figure 5A. The effect of the siRNA on
cell cycle is now under investigation. Furthermore, the siRNA de-
creased the invasion activity of HCT-116 and HT-29 cells to 40%
and 60%, respectively (Figure 4B). When considering that our lipo-
fection efficiency in HCT-116 cells was ∼60%, as assessed by EGFP
expression, the invasion suppression activity of the siRNA in these
cells may be very strong. The molecular mechanism for the activation
of cell invasion with FZD7 is unknown now. One possible explana-
tion for our result is the decreased expression of Wnt target genes
affecting cell invasion activity, which may include CD44 [21], matrix
metalloproteinase 7 (MMP-7 ) [22], MT1-MMP/MMP-14 [23], uro-
kinase plasminogen activator [24], S100A4 [25], etc. Although some
developmental studies have suggested that FZD7 is involved in the
noncanonical Wnt signaling pathway and regulates tissue movement
or cell migration [26,27], its role in human tissues and cancer cells re-
mains to be investigated.
We finally demonstrated the FZD7 expression in primary CRC
tissues (Figure 5B). Although the expression level was various in each
tissue, it was equivalent to that of cell lines in around half of the
cases. Of note, samples #346, 347, and 404 with the lower expres-
sion level were all in stage II, which might suggest the FZD7 expres-
sion in advanced stages.
There has been little knowledge about Wnts that interact with
FZD7 in cancer cells. Very recently, Kim et al. [28] reported that
Wnt3 directly interacts with FZD7 in hepatoma cells. It was previ-
ously shown that Wnt2, Wnt3, and Wnt3a were detected in HCT-
116 cells by RT-PCR [29], Wnt3 may also interact with FZD7 in
CRC cells.
In conclusion, we demonstrated for the first time that FZD7 ac-
tivates the canonical Wnt pathway in colon cancer cells despite the
presence of APC or CTNNB1 mutation and that FZD7-siRNA
could be used as a therapeutic reagent for CRCs.
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